I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 28 day of February 2006

Patricia Litchfield
(Signature of person mailing)

Patricia Litchfield
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: William J. Curatolo, et al.

: Examiner: B. Fubara

SERIAL NO.: 09/770,562 : Art Unit: 1615

FILED: January 26, 2001 :

FOR: Solid Pharmaceutical Dispersions
With Enhanced Bioavailability

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE (AMENDMENT) TO FINAL OFFICE ACTION

This is in response to the Office Action mailed on August 30, 2005 in the above-identified application, the term for response having been extended 3 (three) months to February 28, 2006 by including the appropriate fee and petition herewith.

A current claim summary is appended hereto, starting on its own separate sheet.

Remarks

As a preliminary matter, please note the Request For Continued Examination (RCE) submitted herewith.

The Amendments

Claims 1, 7, 11, 15, 39, 43, 45, and 47 have each been amended to state that the drug:polymer weight ratio is between 1:0.5 and 1:100, as opposed to the former range of 1 to 0.2 to 1 to 100. The amendment thus places the maximum amount of drug in the dispersion at 67% (i.e., 1:0.5), as opposed to the former maximum of 83% (i.e., 1 to 0.2). Support is in the application, specifically Example 9, Table 1, at page 36. Example 9